|
1
|
Weill H, Hughes JM and Churg AM: Changing
trends in US mesothelioma incidence. Occup Environ Med. 61:438–441.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Centers for Disease Control and Prevention
(CDC). Malignant mesothelioma mortality - United States, 1999–2005.
MMWR Morb Mortal Wkly Rep. 58:393–396. 2009.
|
|
3
|
Takeshima Y, Inai K, Amatya VJ, Gemba K,
Aoe K, Fujimoto N, Kato K and Kishimoto T: Accuracy of pathological
diagnosis of mesothelioma cases in Japan: Clinicopathological
analysis of 382 cases. Lung Cancer. 66:191–197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Amatya VJ, Takeshima Y, Aoe K, Fujimoto N,
Okamoto T, Yamada T, Kishimoto T, Morimoto C and Inai K: CD9
expression as a favorable prognostic marker for patients with
malignant mesothelioma. Oncol Rep. 29:21–28. 2013.
|
|
5
|
Pass HI, Vogelzang N, Hahn S and Carbone
M: Malignant pleural mesothelioma. Curr Probl Cancer. 28:93–174.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Robinson BW and Lake RA: Advances in
malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Montanaro F, Rosato R, Gangemi M, Roberti
S, Ricceri F, Merler E, Gennaro V, Romanelli A, Chellini E,
Pascucci C, et al: Survival of pleural malignant mesothelioma in
Italy: A population-based study. Int J Cancer. 124:201–207. 2009.
View Article : Google Scholar
|
|
8
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Drakaki A and Iliopoulos D: MicroRNA gene
networks in Oncogenesis. Curr Genomics. 10:35–41. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Truini A, Coco S, Alama A, Genova C, Sini
C, Dal Bello MG, Barletta G, Rijavec E, Burrafato G, Boccardo F, et
al: Role of microRNAs in malignant mesothelioma. Cell Mol Life Sci.
71:2865–2878. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Busacca S, Germano S, De Cecco L, Rinaldi
M, Comoglio F, Favero F, Murer B, Mutti L, Pierotti M and Gaudino
G: MicroRNA signature of malignant mesothelioma with potential
diagnostic and prognostic implications. Am J Respir Cell Mol Biol.
42:312–319. 2010. View Article : Google Scholar
|
|
12
|
Kubo T, Toyooka S, Tsukuda K, Sakaguchi M,
Fukazawa T, Soh J, Asano H, Ueno T, Muraoka T, Yamamoto H, et al:
Epigenetic silencing of microRNA-34b/c plays an important role in
the pathogenesis of malignant pleural mesothelioma. Clin Cancer
Res. 17:4965–4974. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pass HI, Goparaju C, Ivanov S, Donington
J, Carbone M, Hoshen M, Cohen D, Chajut A, Rosenwald S, Dan H, et
al: hsa-miR-29c* is linked to the prognosis of malignant
pleural mesothelioma. Cancer Res. 70:1916–1924. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gee GV, Koestler DC, Christensen BC,
Sugarbaker DJ, Ugolini D, Ivaldi GP, Resnick MB, Houseman EA,
Kelsey KT and Marsit CJ: Downregulated microRNAs in the
differential diagnosis of malignant pleural mesothelioma. Int J
Cancer. 127:2859–2869. 2010. View Article : Google Scholar :
|
|
15
|
Santarelli L, Strafella E, Staffolani S,
Amati M, Emanuelli M, Sartini D, Pozzi V, Carbonari D, Bracci M,
Pignotti E, et al: Association of miR-126 with soluble
mesothelin-related peptides, a marker for malignant mesothelioma.
PLoS One. 6:e182322011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kirschner MB, Cheng YY, Badrian B, Kao SC,
Creaney J, Edelman JJ, Armstrong NJ, Vallely MP, Musk AW, Robinson
BW, et al: Increased circulating miR-625-3p: A potential biomarker
for patients with malignant pleural mesothelioma. J Thorac Oncol.
7:1184–1191. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Usami N, Fukui T, Kondo M, Taniguchi T,
Yokoyama T, Mori S, Yokoi K, Horio Y, Shimokata K, Sekido Y, et al:
Establishment and characterization of four malignant pleural
mesothelioma cell lines from Japanese patients. Cancer Sci.
97:387–394. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gebäck T, Schulz MM, Koumoutsakos P and
Detmar M: TScratch: A novel and simple software tool for automated
analysis of monolayer wound healing assays. Biotechniques.
46:265–274. 2009.PubMed/NCBI
|
|
19
|
Lamprecht MR, Sabatini DM and Carpenter
AE: CellProfiler: Free, versatile software for automated biological
image analysis. Biotechniques. 42:71–75. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Amatya VJ, Takeshima Y, Kushitani K,
Yamada T, Morimoto C and Inai K: Overexpression of CD26/DPPIV in
mesothelioma tissue and mesothelioma cell lines. Oncol Rep.
26:1369–1375. 2011.PubMed/NCBI
|
|
21
|
Milano MT and Zhang H: Malignant pleural
mesothelioma: A population-based study of survival. J Thorac Oncol.
5:1841–1848. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Furukawa S, Kawasaki Y, Miyamoto M,
Hiyoshi M, Kitayama J and Akiyama T: The miR-1-NOTCH3-Asef pathway
is important for colorectal tumor cell migration. PLoS One.
8:e806092013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han C, Zhou Y, An Q, Li F, Li D, Zhang X,
Yu Z, Zheng L, Duan Z and Kan Q: MicroRNA-1 (miR-1) inhibits
gastric cancer cell proliferation and migration by targeting MET.
Tumour Biol. 36:6715–6723. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nasser MW, Datta J, Nuovo G, Kutay H,
Motiwala T, Majumder S, Wang B, Suster S, Jacob ST and Ghoshal K:
Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression
of tumorigenic property of lung cancer cells and their
sensitization to doxorubicin-induced apoptosis by miR-1. J Biol
Chem. 283:33394–33405. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Karatas OF, Guzel E, Suer I, Ekici ID,
Caskurlu T, Creighton CJ, Ittmann M and Ozen M: miR-1 and miR-133b
are differentially expressed in patients with recurrent prostate
cancer. PLoS One. 9:e986752014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kawakami K, Enokida H, Chiyomaru T,
Tatarano S, Yoshino H, Kagara I, Gotanda T, Tachiwada T, Nishiyama
K, Nohata N, et al: The functional significance of miR-1 and
miR-133a in renal cell carcinoma. Eur J Cancer. 48:827–836. 2012.
View Article : Google Scholar
|
|
27
|
Du YY, Zhao LM, Chen L, Sang MX, Li J, Ma
M and Liu JF: The tumor-suppressive function of miR-1 by targeting
LASP1 and TAGLN2 in esophageal squamous cell carcinoma. J
Gastroenterol Hepatol. Sep 28–2015.(Epub ahead of print).
View Article : Google Scholar
|
|
28
|
Xu Y, Zheng M, Merritt RE, Shrager JB,
Wakelee H, Kratzke RA and Hoang CD: miR-1 induces growth arrest and
apoptosis in malignant mesothelioma. Chest. 144:1632–1643. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xia H, Ooi LL and Hui KM: miR-214 targets
β-catenin pathway to suppress invasion, stem-like traits and
recurrence of human hepatocellular carcinoma. PLoS One.
7:e442062012. View Article : Google Scholar
|
|
30
|
Li B, Han Q, Zhu Y, Yu Y, Wang J and Jiang
X: Down-regulation of miR-214 contributes to intrahepatic
cholangiocarcinoma metastasis by targeting Twist. FEBS J.
279:2393–2398. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang F, Liu M, Li X and Tang H: miR-214
reduces cell survival and enhances cisplatin-induced cytotoxicity
via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett.
587:488–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Srivastava A, Goldberger H, Dimtchev A,
Ramalinga M, Chijioke J, Marian C, Oermann EK, Uhm S, Kim JS, Chen
LN, et al: MicroRNA profiling in prostate cancer - the diagnostic
potential of urinary miR-205 and miR-214. PLoS One. 8:e769942013.
View Article : Google Scholar :
|
|
33
|
Long H, Wang Z, Chen J, Xiang T, Li Q,
Diao X and Zhu B: microRNA-214 promotes epithelial-mesenchymal
transition and metastasis in lung adenocarcinoma by targeting the
suppressor-of-fused protein (Sufu). Oncotarget. 6:38705–38718.
2015.PubMed/NCBI
|
|
34
|
Wang J, Zhang X, Wang L, Yang Y, Dong Z,
Wang H, Du L and Wang C: MicroRNA-214 suppresses oncogenesis and
exerts impact on prognosis by targeting PDRG1 in bladder cancer.
PLoS One. 10:e01180862015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Phatak P, Byrnes KA, Mansour D, Liu L, Cao
S, Li R, Rao JN, Turner DJ, Wang JY and Donahue JM: Overexpression
of miR-214-3p in esophageal squamous cancer cells enhances
sensitivity to cisplatin by targeting survivin directly and
indirectly through CUG-BP1. Oncogene. View Article : Google Scholar : [Epub ahead of
print].
|
|
36
|
Tsukiji H, Takeshima Y, Amatya VJ,
Kushitani K and Inai K: Myogenic antigen expression is useful for
differentiation between epithelioid mesothelioma and non-neoplastic
mesothelial cells. Histopathology. 56:969–974. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hsu SD, Tseng YT, Shrestha S, Lin YL,
Khaleel A, Chou CH, Chu CF, Huang HY, Lin CM, Ho SY, et al:
miRTarBase update 2014: An information resource for experimentally
validated miRNA-target interactions. Nucleic Acids Res.
42D:D78–D85. 2014. View Article : Google Scholar
|
|
38
|
Dhanasekaran SM, Barrette TR, Ghosh D,
Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA and Chinnaiyan
AM: Delineation of prognostic biomarkers in prostate cancer.
Nature. 412:822–826. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Reiser-Erkan C, Erkan M, Pan Z, Bekasi S,
Giese NA, Streit S, Michalski CW, Friess H and Kleeff J:
Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in
pancreatic ductal adenocarcinoma. Cancer Biol Ther. 7:1352–1359.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Warnecke-Eberz U, Bollschweiler E, Drebber
U, Pohl A, Baldus SE, Hoelscher AH and Metzger R: Frequent
down-regulation of pim-1 mRNA expression in non-small cell lung
cancer is associated with lymph node metastases. Oncol Rep.
20:619–624. 2008.PubMed/NCBI
|
|
41
|
Warnecke-Eberz U, Bollschweiler E, Drebber
U, Metzger R, Baldus SE, Hölscher AH and Mönig S: Prognostic impact
of protein overexpression of the proto-oncogene PIM-1 in gastric
cancer. Anticancer Res. 29:4451–4455. 2009.PubMed/NCBI
|
|
42
|
Peltola K, Hollmen M, Maula SM, Rainio E,
Ristamäki R, Luukkaa M, Sandholm J, Sundvall M, Elenius K, Koskinen
PJ, et al: Pim-1 kinase expression predicts radiation response in
squamocellular carcinoma of head and neck and is under the control
of epidermal growth factor receptor. Neoplasia. 11:629–636. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mondello P, Cuzzocrea S and Mian M: Pim
kinases in hematological malignancies: Where are we now and where
are we going? J Hematol Oncol. 7:952014. View Article : Google Scholar : PubMed/NCBI
|
